Scarica l'app Stockscreener
0.9901
3.87%
-0.0399
Allarity Therapeutics Inc Borsa (ALLR) Ultime notizie
ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - The Eastern Progress Online
ALLARITY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. (NASDAQ: ALLR) for potential violations of federal securities laws - The Eastern Progress Online
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - Kilgore News Herald
ALLR Deadline: ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online
Allarity Therapeutics stock hits 52-week low at $1.03 - Investing.com
Allarity Therapeutics stock hits 52-week low at $1.03 By Investing.com - Investing.com UK
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming DeadlinesALLR - Longview News-Journal
Allarity Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Allarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion - GlobeNewswire Inc.
Allarity Therapeutics stock hits 52-week low at $1.14 By Investing.com - Investing.com South Africa
Allarity Therapeutics stock hits 52-week low at $1.14 - Investing.com
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, I - GuruFocus.com
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus.com
Allarity Therapeutics stock hits 52-week low at $1.25 By Investing.com - Investing.com Canada
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements - GlobeNewswire
Allarity's Phase 2 Cancer Drug Shows Promise: Patients Exceed 14-Month Treatment | ALLR Stock News - StockTitan
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights - The Manila Times
Allarity Therapeutics Reports $18.5M Cash Position, Extended Runway in Q3 Results | ALLR Stock News - StockTitan
FINAL REMINDER ALLR DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Allarity Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit! - AccessWire
DEADLINE ALERT for ALLR, and COIN: The Law Offices of Frank - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - Business Wire
FINAL ALLR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Allarity Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - AccessWire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - Markets Insider
ALLR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, - GlobeNewswire
ALLR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. - The Bakersfield Californian
ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR) - Business Wire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - PR Newswire
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):